Cardiovascular Disease Risk Prediction With and Without Knowledge of Genetic Variation at Chromosome 9p21.3

  1. Nina P. Paynter, PhD;
  2. Daniel I. Chasman, PhD;
  3. Julie E. Buring, ScD;
  4. Dov Shiffman, PhD;
  5. Nancy R. Cook, ScD; and
  6. Paul M. Ridker, MD, MPH
  1. From Brigham and Women's Hospital, Boston, Massachusetts, and Celera, Alameda, California.
    1. Figure.
      View larger version:
        Figure. Kaplan–Meier survival curves for cardiovascular disease, by rs10757274 genotype.

        ATP III = Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.

      Responses to this article

      • In Response:
        • Nina P. Paynter and
        • Nancy R. Cook, ScD, and Paul M Ridker, MD, MPH
        Ann Intern Med published online October 26, 2009
      • Paynter study does indeed support use of 9p21 for cardiovascular risk
        • Jeff Gulcher and
        • Kari Stefansson, MD PhD deCODE Genetics
        Ann Intern Med published online October 26, 2009
      • Comments on: Cardiovascular Disease Risk Prediction...
        • Lukasz Kiljanek
        Ann Intern Med published online October 26, 2009
      • Screening
        • John R. Schwarzenbach
        Ann Intern Med published online October 26, 2009

      Summary for Patients

      • Summaries for Patients:Does Measuring Genetic Variations at Chromosome 9p21.3 Help to Predict Cardiovascular Disease in Women? Ann Intern Med January 20, 2009 150:I-36; doi:10.1059/0003-4819-150-2-200901200-00001
      « Previous | Next Article »Table of Contents

      This Article

      1. Ann Intern Med January 20, 2009 vol. 150 no. 2 65-72
      1. AbstractFREE
      2. » Figures
      3. Full Text
      4. Full Text (PDF)
        1. Summary for Patients

      Current Issue

      1. December 1, 2009, 151 (11)
      1. Alert me to current issues